Focus: Pierre Fabre is a French specialty pharmaceutical company founded in 1962, focused on oncology and dermatology/cosmetics with a diversified but geographically dispersed portfolio. The company operates 220 active job openings and maintains a presence across R&D, commercial, and manufacturing.
Profile data last refreshed 22h ago · AI intelligence enriched 1mo ago
Hot — 429 jobs added in 30d
Net +280 (429 new, 149 removed). Aggressive expansion phase.
Pierre Fabre offers oncology and dermatology expertise in a stable European pharma with growth hiring, but the single-product revenue dependency and imminent patent cliff present material restructuring risk unless pipeline programs accelerate.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Pierre Fabre
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Pierre Fabre's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Only approved revenue-generating product; patent cliff in October 2028 eliminates 100% of disclosed Part D revenue.
Local anesthetic NDA with no disclosed Part D spending; lifecycle approaching loss of exclusivity.
Oncology NDA with supporting Phase 2 and Phase 3 trials; generic competition approaching.
Post-LOE generic chemotherapy product; no new revenue potential.
2 discontinued, 0 duplicate formulations not shown
Regulatory tracker: Viatris' Ryzumvi wins FDA nod in age-related vision loss - Fierce Pharma
Regulatory tracker: Viatris' Ryzumvi wins FDA nod in age-related vision loss Fierce Pharma
/C O R R E C T I O N - Pierre Fabre Pharmaceuticals/ - Yahoo Finance
/C O R R E C T I O N - Pierre Fabre Pharmaceuticals/ Yahoo Finance
Atara, Pierre Fabre take third shot at FDA approval of Ebvallo - BioWorld News
Atara, Pierre Fabre take third shot at FDA approval of Ebvallo BioWorld News
PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval - Yahoo Finance
PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval Yahoo Finance
Pierre Fabre Pharmaceuticals Resubmits Tabelecleucel Biologics License Application for Treatment of Epstein-Barr Virus Positive-Post-Transplant Lymphoproliferative Disease to the FDA - PR Newswire
Pierre Fabre Pharmaceuticals Resubmits Tabelecleucel Biologics License Application for Treatment of Epstein-Barr Virus Positive-Post-Transplant Lymphoproliferative Disease to the FDA PR Newswire
8-K Filing: LIGAND PHARMACEUTICALS INC (LGND, LGNDZ, LGNXZ, LGNYZ, LGNZZ) (CIK 0000886163) — EX-99.2
EX-99.2
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Rapid and selective characterization of antibody-drug conjugates in complex sample matrices by native affinity liquid chromatography-mass spectrometry.
A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAF(V600E) mutated metastatic non-small cell lung cancer: Results from the OCEAN II study.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo